

RECEIVED
REGION 1

2006 AUG 18 PM 12: 47

August 16, 2006

Br. 2

Thomas K. Thompson
Senior Health Physicist
Division of Nuclear Materials Safety
U.S. Nuclear Regulatory Commission-Region I
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

29-30350-01
030 34280

SUBJECT: XENOGEN CORPORATION, CONSENT TO TRANSFER LICENSE,
CONTROL NO. 138731

Dear Mr. Thompson:

The purpose of this letter is to inform you that both Caliper's and Xenogen Corporation's stockholders have approved the acquisition of Xenogen by Caliper, and that the acquisition was completed as of August 9, 2006. Please make the appropriate changes to Material License 29-30350-01 as outlined in a letter received by the U.S. NRC on April 21, 2006. This letter described the proposed transfer of licensed activities.

Please do not hesitate to call me if you have any questions or comments about the acquisition. I can be contacted at Xenogen Biosciences at (609) 235-1442.

Sincerely,

Joseph D'Ippolito

Joseph D'Ippolito
EH&S Specialist, Radiation Safety Officer
Xenogen Biosciences

cc.:

Bruce Bal, Senior Vice President of Operations, Caliper Life Sciences

(Ref. 138731)

139289
NMSS/RGNI MATERIALS-002

This is to acknowledge the receipt of your letter/application dated

8/16/2006, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment 29-30350-01 There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 139299.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (R)
(6-98)

Sincerely,
Licensing Assistance Team Leader